Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escalated single platelet inhibition plus direct oral anticoagulation after PCI in atrial fibrillation with acute myocardial infarction
2020-004748-27Phase 4Active
- Sponsor
- LMU Klinikum
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of prasugrel, ticagrelor, clopidogrel and aspirin in Atrial fibrillation (AFib), acute coronary syndrome (ACS) and myocardial infarction (MI) (2 arms), sponsored by LMU Klinikum. Primary endpoint: Primary endpoint at 6 weeks after randomization. Started Jan 2022; status: active.
02
Drugs
prasugrelticagrelorclopidogrelaspirin
03
Conditions
Atrial fibrillation (AFib)acute coronary syndrome (ACS)myocardial infarction (MI)
Beyond the preview
Go deeper on 2020-004748-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004748-27.